GlycoNex reports positive results for denosumab biosimilar Phase I trial

Taiwanese biotechnology company GlycoNex has reported positive results from a Phase I clinical trial of its denosumab biosimilar, SPD8.

Conducted in collaboration with Mitsubishi Gas Chemical (MGC), the Phase I trial enrolled healthy postmenopausal women and met its primary endpoint of clinical pharmacokinetic equivalence.